



Cite this: *RSC Adv.*, 2018, 8, 41663

Highly conjugated architectures and labile reaction intermediates from coupling between 10π electron-deficient heteroaromatics and *sym*-trihydroxy- or triamino-benzene derivatives†

Gabriele Micheletti,^a Carla Boga,^a Silvia Cino,^a Silvia Bordoni^a and Elena Chugunova^{b,c}

The C–C coupling reaction between neutral aromatic carbon nucleophiles such as 1,3,5-triamino- and 1,3,5-trihydroxy-benzene derivatives and 7-chloro-4,6-dinitrobenzofuroxan (Cl-DNBF) or 7-chloro-4,6-dinitrobenzofurazan (Cl-DNBZ) gave in high yield the corresponding conjugated structures, which are of potential interest in the materials field. When chlorine is absent on the electrophile, as in 4,6-dinitrobenzofurazan (DNBF), the reaction with 1,3,5-triaminobenzene derivatives produces Wheland–Meisenheimer (WM) zwitterionic intermediates, intercepted and fully characterized via NMR at low temperature, whereas stable Meisenheimer complexes (M) were isolated in the reaction of phloroglucinol with 1,3,5-trimethoxybenzene. The latter also gave exclusively M complexes when reacted with 4,6-dinitrobenzofuroxan (DNBF), or 4,6-dinitrotetrazolopyridine (DNTP). The detection of WM or M intermediates can be rationalized by invoking the substituent stabilization ability of the positive charge in WM intermediates, on going from neutral carbon nucleophiles 1,3,5-triaminobenzenes to 1,3,5-trihydroxybenzene derivatives. Furthermore, variable-temperature NMR experiments on the M intermediates gave insights into the rotational barrier about the newly formed C–C bond.

Received 16th November 2018
Accepted 6th December 2018

DOI: 10.1039/c8ra09460h


rsc.li/rsc-advances

Introduction

Benzofurazan and benzofuroxan derivatives are heterocyclic compounds, which possess interesting properties useful for different applications in many applied fields. For example, they exhibit a broad spectrum of biological activities including antibacterial, antifungal, antileukemic, and acaricide activities. Benzofuroxans are also of great interest as NO donors^{1–4} and have found applications as dyes, fluorescent biosensors and high energy materials.^{5,6}

Due to the 10π -electron ring heteroaromatic structure,⁷ they behave also as electrophiles and they have been classified as superelectrophilic heteroaromatic compounds^{8,9} when one or more nitro groups are bound to the carbocyclic ring. For this peculiarity, they are of great interest from the mechanistic point of view. For instance, the 4,6-

dinitrobenzofuroxan (DNBF) ring is able to stabilize the negative charge in the Meisenheimer complexes.^{7,10–12} Furthermore, when DNBF was combined with neutral aromatic nucleophilic species, such as triaminobenzene derivatives 1–3, the detection and characterization of WM intermediates (Scheme 1), simultaneously Wheland type on the nucleophilic moiety and Meisenheimer on the electrophilic one, was achieved for the first time.¹³



Scheme 1 Formation of Wheland–Meisenheimer complexes (WMA–WMC) from the reaction between 1,3,5-tris(*N,N*-dialkylamino) benzenes and DNBF.

^aDepartment of Industrial Chemistry 'Toso Montanari', Alma Mater Studiorum Università di Bologna, Viale Del Risorgimento, 4, 40136 Bologna, Italy. E-mail: gabriele.micheletti3@unibo.it

^bArbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, Akad. Arbuzovst. 8, Kazan, Tatarstan 420088, Russia

^cKazan Federal University, 18 Kremlyovskaya St., Kazan, Tatarstan 420008, Russia

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra09460h







Fig. 1 Salts derived from the reaction between equimolar amount of 1–3 and 4.

18%, respectively, in the case of 1 or 2 after 96 h. The increased electrophilicity of Cl-DNBF, due to the presence of the additional EWG nitro group with respect to ClNBZ, is likely responsible of the higher conversion and shorter reaction time.

The comparison of the results obtained by 7-chloro-4,6-dinitrobenzofuroxan with those obtained with 4-chloro-7-nitrobenzofuroxan instead of 4-chloro-7-nitrobenzofuroxan is permitted taking into account that Cl-DNBF⁴⁸ and Cl-DNBZ⁸ have the same Mayr's electrophilicity value ($E_{\text{Mayr}} = -6.11$).

Finally, we carried out the reaction between 1–3 and 4 by direct mixing of the reagents in the NMR spectroscopy tube at low temperature to eventually trap reaction intermediates. Previously, the coupling between 1–3 and 4,6-dinitrobenzofuroxan (DNBF) allowed the NMR detection at low temperature of the first Wheland–Meisenheimer complexes (WM1–3 in Scheme 1).¹³ Although we were aware that the occurrence of a chlorine atom in the 7-chloro-4,6-dinitrobenzofuroxan, causing good leaving group in S_NAr, makes hard the challenge to intercept the zwitterionic WM species (Scheme 3), the ability of amino group in stabilizing the positive charge enables the intent to spectroscopically intercept the W intermediate (Scheme 3). It has to be noted that similar stable intermediates have been previously observed in the reaction between 3 and ClNBZ.⁴⁷

First, our strategy pursued to select 4 to be reacted with 3, since it is well known that the latter is able to stabilize the positive charge of Wheland intermediates. In this case, the ¹H



Scheme 3 Possible intermediates (WM and W) from the reactions between 1–3 and 4.

NMR spectrum, recorded in CD₂Cl₂ at -70 °C, as the reactants were mixed, showed a set of signals compatible with those of the salt 8H⁺Cl⁻ (Fig. 1). In particular, a broad singlet at $\delta = 11.35$ ppm was ascribed to the NH signal and the presence of a singlet at $\delta = 8.9$ ppm and of two singlets at $\delta = 6.02$ and 5.96 ppm (integrating 1 : 1 : 1) was attributed to the proton belonging to the benzofuroxanyl moiety and to the aromatic protons of the triaminobenzene moiety, respectively.


The latter resulted not equivalent due to the restricted rotation around the new C–C bond formed, as also confirmed by the splitting of the signals of the methylene hydrogen atoms of the pyrrolidinyl moiety in the aliphatic region. On raising the temperature, the two singlets belonging to the hydrogen atoms on the aminobenzene moiety and those of the pyrrolidinyl groups, gradually broadened until coalescence at about -43 °C; above this value they gradually sharpened. The spectrum exhibited further signals increasing the temperature from $+2$ °C to $+25$ °C, indicating a possible evolution to unidentified compounds, explaining the failure of our previous attempts to isolate 8.

An analogous behavior was observed when the reaction between 2 and 4 was carried out at -88 °C in CD₂Cl₂: after reaction mixture the ¹H NMR spectrum showed disappearance of the reactant signals and appearance of new signals at $\delta = 8.98$, 7.52, and 6.39 ppm in the aromatic region integrating 1 : 1 : 1, respectively, attributable to the salt 7H⁺Cl⁻. The morpholinyl signals, at this temperature, were distinct due to the restricted rotation around the new formed C–C bond. On gradually raising the temperature, as observed in the previous case, the signals belonging to the aminobenzene moiety gradually sharpened, and the coalescence situation was reached around -37 °C. The phenomenon was reversible on gradually lowering the temperature from 25 °C until -88 °C, since the final spectrum was equal to that obtained after mixing the two reagents at the same temperature. When the sample has been extracted from the NMR probe, a solid was observed on the bottom of the NMR tube; after filtration, it was dissolved in CD₃CN and analyzed through ¹H, ¹³C NMR and DEPT experiments and its spectral data were consistent with those of structure 7H⁺ (Fig. 1). This solid was percolated through Al₂O₃ eluting with acetonitrile and the ¹H NMR spectrum of the residue was in agreement with that of the neutral form 7.

Reactions with 1,3,5-trihydroxybenzene derivatives 12 and 13. The reaction between 1,3,5-trihydroxybenzene (12, phloroglucinol) and Cl-DNBF (4) (Scheme 4), was run, by directly adding the reagents in equimolar amount, dissolved in CD₃CN in the NMR spectroscopy tube at room temperature: after 15 min the ¹H NMR spectrum of the crude showed a 30 : 70 relative % molar ratio of residue reactants (4 or 12) and the coupling product 14. The hydrogen relative signal integration between compounds 4 and 14, became approximately 1 : 4, after 5 h and the conversion appeared almost complete after 24 h. Analogous behavior was observed for the reaction between 5 and 12, yielding 16.

The reaction between 1,3,5-trimethoxybenzene (13) and 4 (Scheme 4) was carried out under the analogous conditions used for phloroglucinol: after 15 min, the spectrum showed





Scheme 6 Zwitterionic reaction intermediates WM4 and WM5 formed from 18 and 19 and structure of other possible intermediates.

between **1** and **18** was also carried out in CD_2Cl_2 at -80°C . As previously reported for **WMa-c**,^{13,14} the signal belonging to H-7 atom remained sharp on varying the temperature. Furthermore, **WM1-WM5** resulted to be unstable when kept in CDCl_3 at 25°C overnight, since the solution presents several ^1H NMR signals, belonging to unidentified compounds.


Reactions of 4,6-dinitrobenzofuroxan (DNBF), 4,6-dinitrotetrazolopyridine (DNTP), and 4,6-dinitrobenzofurazan (DNBZ) with 1,3,5-trihydroxybenzene (**12**) and 1,3,5-trimethoxybenzene (**13**)

Based on previous and current findings, which have shown the formation of **WM** intermediates at low temperature between **1-3** and 4,6-dinitrobenzofuroxan (**DNBF**),¹³ 4,6-dinitrotetrazolopyridine (**DNTP**),⁴³ or 4,6-dinitrobenzofurazan (**DNBZ**, see above section), we planned to investigate the behavior of the above electrophiles with **12** and **13**. Each nucleophile/electrophile combination was realized by adding the two reagents directly in the NMR spectroscopy tube at low temperature (-35°C in CD_3CN , or -80°C in acetone- d_6 for the **DNBZ/12** couple) and by ^1H NMR monitoring. In all cases, the Meisenheimer **M1-M6** complexes (Scheme 7) were observed and characterized by ^1H NMR, ^{13}C NMR, DEPT and/or g -HSQC experiments. In most cases, due to the poor stability in solution at room temperature of these intermediates, the ^{13}C NMR spectrum was recorded at low temperature.

Although the first step of the $\text{S}_{\text{N}}\text{Ar}/\text{S}_{\text{E}}\text{Ar}$ reaction consists in the formation of the **WM** intermediate, the detection of only the **M1-M6** intermediates by NMR measurements at low temperature indicates that **WM6-WM11** species, derived from the coupling with **12** or **13** (Scheme 7), are less stable than **WM1-WM5** (Schemes 5 and 6). The presence of hydroxy- or methoxy-substituents on the carbocyclic ring of **12** and **13** causes very elusive species on the NMR time-scale detection due to the minor stabilization of the Wheland moiety positive charge by hydroxy (or methoxy) substituents with respect to the amino substituents. On the other hand, the **M1-M6** anionic intermediates resulted stable enough, due to the ability to stabilize the negative charge by the moieties derived from **DNBF**, **DNBZ**, and **DNTP**.

Moreover, the ^1H NMR spectra recorded at low temperature showed non-equivalence of the hydrogen atoms belonging to the nucleophilic moiety of **M1-M6** and, in case of **M2**, **M4**, and **M6** to methyl groups also. This may be ascribed to rotational constraints at low temperature, about the C-C bond, formed between the nucleophilic and the electrophilic moiety. Coalescence phenomenon was observed on raising temperature, then the signals gradually sharpened. From the proton NMR spectra of **M1-M6**, recorded under dynamic conditions, the free activation energy (ΔG^\ddagger) was derived by means of the Eyring equation.⁵⁶ The Fig. 2 shows the line shape simulation for **M2** and the ΔG^\ddagger values obtained are reported in Table 1.





Scheme 7 Reaction intermediates from the reactions of 12 and 13 with DNBF, DNBZ, and DNTP.

The ΔG^\ddagger values obtained are in line with those commonly reported for rotational processes.⁵⁷ In particular, slightly different values have been found on changing the electrophile,




Fig. 2 Left: experimental variable temperature ¹H NMR spectra in CDCl₃ of **M2**. Right: line-shape simulation obtained with the rate constant indicated. The reported real spectra results partially hidden by the signal of residual starting material.

but appear almost the same by altering the nucleophilic moiety; thus indicating that the rotational constraints are independent from the hydroxy- or methoxy- substituents on the nucleophilic moiety.

Concerning the formation of the σ -adducts, the **M2** and **M4** have previously been obtained by Terrier and coll. in DMSO.⁵⁵ In the case of **M2**, the authors observed the spontaneous oxidation to **15** in 50% yield in the same solvent. In the current case, adducts **M2** and **M4** have instead been prepared in CD₃CN solution, and **M2** undergo departure of the hydride ion to be completed in about three days. Evolution to **15** was confirmed by spectral data comparison of authentic **15** obtained as shown in Scheme 4. Analogous behavior has been observed for the reaction of **13** with **DNBZ**. These findings agree with those previously reported⁵⁵ about the facile oxidation of some **DNBF** and **DNBZ** σ -adducts and provide further examples of formal hydride displacement from an aromatic ring.

Table 1 ΔG^\ddagger values for the rotational process around the C–C bond in intermediates **M1**–**M6**

	ΔG^\ddagger (kcal mol ⁻¹)	Solvent
M1	13.2 ± 0.2	CD ₃ CN
M2	13.2 ± 0.2	CD ₃ CN
M3	13.9 ± 0.2	CD ₃ COCD ₃
M4	14.1 ± 0.2	CD ₃ CN
M5	12.4 ± 0.2	CD ₃ CN
M6	12.5 ± 0.2	CD ₃ CN



Conclusions

New compounds, interesting for several potential applications, have been obtained in good yield by aromatic substitution reaction of triamino- and trihydroxybenzene derivatives with 7-chloro-4,6-dinitrobenzofuroxan (**Cl-DNBF**) and 7-chloro-4,6-dinitrobenzofurazan (**Cl-DNBZ**).

Novel **WM** intermediates from the reaction between 1,3,5-triaminobenzenes and 4,6-dinitrobenzofurazan (**DNBZ**) have been detected and characterized by NMR.

Contrarily to what observed by reacting 1,3,5-triaminobenzene derivatives and 4,6-dinitrobenzofuroxan, 4,6-dinitrobenzofurazan, or 4,6-dinitrotetrazolopyridine, the reactions between the latter electrophiles and 1,3,5-trihydroxybenzene (or 1,3,5-trimethoxybenzene), carried out directly at low temperature in the NMR tube, did not evidence Wheland–Meisenheimer intermediates, but solely Meisenheimer complexes **M1–M6**. The different behaviour with respect to that of triaminobenzene derivatives may be devoted to the lower ability to stabilize positive charge on the nucleophilic moiety of **WM** intermediates in the hydroxy- or methoxy-substituted benzene species. Further, the low temperature NMR dynamic behaviour of **M1–M6** species showed non-equivalent signals, which, increasing the temperature, gradually broadened to a coalescence situation, until they sharpen again. The observed spectra allowed determine the free activation energy of the restricted rotational process at low temperature.

Experimental section

The ^1H and ^{13}C NMR spectra were recorded with a Mercury 400 and Inova 600 (Varian, Palo Alto USA) spectrometers operating at 400, or 600 MHz (for ^1H NMR) and 100.56, or 150.80 MHz (for ^{13}C NMR), respectively. J values are given in hertz (Hz). Signal multiplicities were established by DEPT experiments. Chemical shifts were referenced to the solvent [$\delta = 5.31$ and 53.8 ppm for CD_2Cl_2), ($\delta = 1.96$ and 118.2 ppm for CD_3CN), ($\delta = 2.50$ and 39.5 ppm for CD_3SOCD_3), ($\delta = 2.10$ and 30.2 ppm for CD_3COCD_3), and ($\delta = 7.26$ and 77.0 ppm for CDCl_3) for ^1H and ^{13}C NMR, respectively].

The variable-temperature NMR spectra and 2D low temperature spectra were recorded on Mercury 400 or Inova 600 instruments with a direct PFG Probe. The temperatures were calibrated by substituting the sample with a precision Cu/Ni thermocouple before the measurements. Complete fitting of dynamic NMR line shapes was carried out using a PC version of the DNMR-6 program.⁵⁸

ESI-MS spectra were recorded with a WATERS 2Q 4000 instrument. Chromatographic purifications were carried out on silica gel (0.037–0.063 mm, Merck) columns at medium pressure. Thin layer chromatography (TLC) was performed on silica gel 60 F254 coated aluminum foils (Fluka). Melting points were measured on a Stuart SMP3 apparatus and are uncorrected. Solvents were commercial materials (Aldrich or VWR International) if not specified. 1,3,5-Tris(dialkylamino)benzenes **1–3** were prepared as described previously.¹³ 7-Chloro-4,6-dinitrobenzofuroxan (**Cl-DNBF**, **4**),^{3b} **DNBF**,¹² **DNBZ**,¹² and **DNTP**¹⁴ were synthesized and purified as described in the literature.

Synthesis of 7-chloro-4,6-dinitrobenzofurazan (5)

In a three-necked round bottom flask, equipped with thermometer, dropping funnel, and kept in an ice bath, 0.5 g of 4-chloro-7-nitrobenzofurazan (**CINBZ**) were introduced and dissolved in conc. H_2SO_4 96% (7 mL). The solution was magnetically stirred then a solution of conc. HNO_3 65% (0.75 mL) conc. H_2SO_4 96% (2 mL) was slowly drop-wise added. The reaction temperature was maintained at 0°C during the addition of the sulfonitric mixture. Then the mixture was increased until 40°C and kept at this temperature for 12 h. The reaction mixture was put into a becker with ice and, once the ice was fused, the solid obtained was isolated by filtration on Buchner funnel, washed with water until the pH of filtrate was neutral, and dried in a desiccator. Chemico-physical data of the solid agreed with literature data.⁵⁹

General procedure for the synthesis of compounds 6–8 and related salts

To a solution of 1,3,5-triaminobenzene derivative (6×10^{-5} mol) in CDCl_3 (10 mL), 1.3 eq. of sodium bicarbonate and an equimolar amount of 7-chloro-4,6-dinitrobenzofuroxan (**4**) were added at room temperature. The mixture was magnetically stirred and the reaction progress was monitored through TLC and ^1H NMR analysis. After solvent removal, the reaction products were purified by column chromatography on silica gel (FC). Compound **6** was obtained using as eluent first a 6/4 diethyl ether/light petroleum and then diethyl ether; in the case of compound **7**, the eluent was diethyl ether/ethyl acetate (1/1). In the case of the reaction between **3** and **4**, due to the formation of many compounds, only traces of a compound which ^1H NMR spectrum, reported below, is compatible with that of **8**, were obtained.

The reaction between equimolar amount of **1** and **4** was carried out also in CDCl_3 directly in the NMR spectroscopy tube without base and the corresponding salt **6H⁺Cl⁻** was obtained. Picrate salt of **6** (**6H⁺picrate**) was obtained by adding to **6** equimolar amount of picric acid. The reaction between equimolar amount (7.7×10^{-5} mol) of **1** and **4** dissolved in CH_2Cl_2 (6 mL) was carried out also at room temperature: immediately the colour of the solution became dark green and after one night a green solid precipitated and was isolated by filtration. Its chemico-physical data agreed with those of compound **6H⁺Cl⁻**. A solution of this solid was percolated through Al_2O_3 (eluent: CH_3CN) and the ^1H NMR spectrum of the residue was equal to that of the neutral form **6**. Analogous behavior was observed for the reaction between **2** and **4**. Chemico-physical data of the obtained compounds are reported below.

4,6-Dinitro-7-(2,4,6-tripiperidin-1-ylphenyl)-2,1,3-benzoxadiazole 1-oxide (6). Dark green solid, 85% yield, mp $> 180^\circ\text{C}$ (dec.) ^1H NMR (CDCl_3 , 400 MHz, 25°C), δ (ppm): 8.90 (s, 1H), 6.36 (s, 2H), 3.33 (t, $J = 4.86$ Hz, 4H), 2.75–2.57 (m, 8H), 1.78–1.60 (m, 4H), 1.41–1.18 (m, 14H). ^{13}C NMR (CDCl_3 , 100.56 MHz, 25°C), δ (ppm): 155.59, 155.56, 145.1, 141.7, 134.2, 132.5, 128.6, 115.0, 107.9, 102.0, 54.4, 48.9, 26.5, 25.8, 24.4, 24.2. MS (ES^+) m/z : 552 [$\text{M} + \text{H}$] $^+$, 574 [$\text{M} + \text{Na}$] $^+$, 590 [$\text{M} + \text{K}$] $^+$; HRMS calc. for $\text{C}_{27}\text{H}_{34}\text{N}_7\text{O}_6$ $^+$: 552.2565; found: 552.2562.



4,6-Dinitro-7-(4-(piperidin-1-ium-1-yl)-2,6-di(piperidin-1-yl)phenyl)benzo[c][1,2,5]oxadiazole 1-oxide chloride ($6\text{H}^+\text{Cl}^-$). ^1H NMR (CDCl_3 , 600 MHz, 25 °C), δ (ppm): 8.90 (s, 1H), 7.31 (br.s., 2H), 3.60–3.30 (m, 4H), 2.75–2.66 (m, 4H), 2.66–2.56 (m, 4H), 2.00–1.60 (m, 6H), 1.42–1.32 (m, 4H), 1.32–1.17 (m, 8H). ^{13}C NMR (CDCl_3 , 150 MHz, 25 °C), δ (ppm): 155.2, 153.6, 144.4, 142.3, 134.3 (br.s.), 132.0 (br.s.), 127.7 (CH), 114.1, 108.3 (br.s.), 90.8 (CH), 53.9 (br.s.), 26.1 (br.s.), 23.6 (br.s.).

1-[3-(3,4-Dihydropyridin-1(2H)-yl)-4-(3-oxido-4,5,6,7-tetrahydro-2,1,3-benzoxadiazol-4-yl)-5-piperidin-1-ylphenyl]piperidinium 2,4,6-trinitrobenzenolate ($6\text{H}^+\text{picrate}$). ^1H NMR (CDCl_3 , 600 MHz, 25 °C), δ (ppm): 9.01 (s, 2H), 8.90 (s, 1H), 6.86 (s, 2H), 3.56 (t, $J = 5.51$ Hz, 4H), 2.69–2.58 (m, 4H), 2.58–2.48 (m, 4H), 2.10–2.00 (m, 4H), 1.80–1.70 (m, 2H), 1.40–1.18 (m, 12H); ^{13}C NMR (CDCl_3 , 150 MHz, 25 °C), δ (ppm): 158.6, 155.4, 149.2, 144.5, 142.4, 140.3, 134.5, 132.0, 127.8 (CH), 126.5, 126.4 (CH), 116.0, 114.2, 106.7 (CH), 55.2 (CH_2), 54.0 (CH_2), 26.2 (CH_2), 24.1 (CH_2), 23.7 (CH_2), 22.5 (CH_2).

4,6-Dinitro-7-(2,4,6-trimorpholin-4-ylphenyl)-2,1,3-benzoxadiazole 1-oxide (7). Dark green solid, 85% yield, mp > 180 °C (dec.). ^1H NMR (CDCl_3 , 400 MHz, 25 °C): δ (ppm): 8.88 (s, 1H), 6.45 (s, 2H), 3.89 (t, $J = 4.6$ Hz, 4H), 3.48–3.36 (m, 8H), 3.34 (t, $J = 4.9$ Hz, 4H), 2.80–2.63 (m, 8H); ^{13}C NMR (CDCl_3 , 100.56 MHz, 25 °C) δ (ppm): 154.3, 153.8, 144.4, 142.5, 133.9, 132.1, 127.7, 127.3, 114.3, 103.0, 66.8, 66.3, 52.9, 48.3. MS (ES^+) m/z : 558 [$\text{M} + \text{H}$] $^+$, 580 [$\text{M} + \text{Na}$] $^+$, 596 [$\text{M} + \text{K}$] $^+$; HRMS calcd for $\text{C}_{24}\text{H}_{28}\text{N}_7\text{O}_9^+$: 558.1943; found: 558.1940.

7-(2,6-Dimorpholino-4-(morpholino-4-ium)phenyl)-4,6-dinitrobenzo[c][1,2,5]oxadiazole 1-oxide chloride ($7\text{H}^+\text{Cl}^-$). Dark green solid, ^1H NMR (CD_2Cl_2 , 400 MHz, 25 °C), δ (ppm): 8.91 (s, 1H), 7.19 (s, 2H), 4.16 (t, $J = 4.6$ Hz, 4H), 3.41–3.34 (m, 4H), 3.42–3.30 (m, 8H), 2.78–2.70 (m, 4H) 2.70–2.62 (m, 4H); ^1H NMR (CD_3CN , 400 MHz, 25 °C), δ (ppm): 8.85 (s, 1H), 7.02 (s, 2H), 4.02 (t, $J = 4.7$ Hz, 4H), 3.50 (m, t, $J = 4.7$ Hz, 4H), 3.41–3.30 (m, 8H), 2.77–2.65 (m, 8H); ^{13}C NMR (CD_3CN , 100.56 MHz, 25 °C), δ (ppm): 154.6, 151.1 (br.s.), 146.0, 144.1, 136.0, 131.3, 129.7, 129.5, 115.2, 107.0 (br.s.), 67.3, 65.8 (br. s.), 53.3, 52.0 (br.s.).

4,6-Dinitro-7-(2,4,6-tripyrrolidin-1-ylphenyl)-2,1,3-benzoxadiazole 1-oxide (8). ^1H NMR (CDCl_3 , 400 MHz, 25 °C), δ (ppm): 8.98 (s, 1H), 5.96 (s, 2H), 3.42–3.35 (m, 4H), 2.95–2.80 (m, 4H), 2.06–1.97 (m, 4H) 1.75–1.55 (m, 8H). The signals in the ^1H NMR spectrum of the mixture obtained by adding in the NMR tube equimolar amount of 3 and 4, and ascribable to $8\text{H}^+\text{Cl}^-$ are the following: ^1H NMR (CD_2Cl_2 , 400 MHz, 0 °C), δ (ppm): 8.87 (s, 1H), 6.22 (s, 2H), 3.52–2.80 (m, 12H), 2.23–1.70 (m, 12H).

Variable temperature NMR experiments for the reaction between 1–3 and 5. Typical procedure

Cl-DNBF (4, 0.038 mmol) was dissolved in CD_2Cl_2 (1 mL) and introduced in a NMR spectroscopy tube, that was inserted in the NMR probe. When the probe temperature reached -88 °C, an equimolar amount of 1,3,5-tris(morpholinyl)benzene (2) was added to the solution, that became blue then dark green, and the ^1H NMR spectrum of the resulting solution was quickly recorded. The system was monitored with times and the spectra

were recorded at different temperatures until 25 °C was reached. The spectra showed the presence of signals ascribable to the salt $7\text{H}^+\text{Cl}^-$. At low temperature the signals in the spectrum showed non-equivalence of the hydrogen atoms belonging to the carbocyclic ring; on raising the temperature the signals broadened until to reach a coalescence situation. After, the peaks became sharp and a re-cooling produced again their broadening until to their splitting as observed after the reagents mixing at low temperature. The systems were monitored until no further change could be detected in the recorded spectra.

General procedure for the synthesis of compounds 9–11

To a solution of 1,3,5-triaminobenzene derivative (0.14 mmol) in CD_3CN (10 mL), 7-chloro-4,6-dinitrobenzofurazan (5, 0.07 mmol) was added at room temperature. The mixture was magnetically stirred and the reaction progress was monitored through TLC and ^1H NMR analysis. After solvent removal, the reaction products were purified by column chromatography on silica gel (FC). Compound 9 was obtained using dichloromethane as eluent; in the case of compound 10, the eluent was dichloromethane/ethyl acetate (from 10/1 until 8/2). In the case of the reaction between 3 and 5, due to its easy decomposition to many unidentifiable compounds, compound 11 was only characterized by ^1H NMR of the crude reaction mixture after solvent removal.

5,7-Dinitro-4-(2,4,6-tri(piperidin-1-yl)phenyl)benzo[c][1,2,5]oxadiazole (9). Dark blue solid, 75% yield, mp > 180 °C (dec.). ^1H NMR (CD_3CN , 599.7 MHz, 25 °C), δ (ppm): 8.94 (s, 1H), 6.55 (s, 2H), 3.38–3.31 (m, 4H), 2.72–2.64 (m, 4H), 2.64–2.56 (m, 4H), 1.74–1.63 (m, 6H), 1.34–1.25 (m, 6H), 1.20–1.10 (m, 6H). ^{13}C NMR (CD_3CN , 100.6 MHz, 25 °C, selected data), δ (ppm): 155.5, 135.4, 128.7 (CH), 104.1 (CH), 54.2 (NCH_2), 49.7 (NCH_2), 26.7 (NCH_2CH_2), 26.2 (NCH_2CH_2), 24.9 ($\text{NCH}_2\text{CH}_2\text{CH}_2$), 24.5 ($\text{NCH}_2\text{CH}_2\text{CH}_2$). MS (ES^+) m/z : 536 [$\text{M} + \text{H}$] $^+$, 558 [$\text{M} + \text{Na}$] $^+$; HRMS calc. for $\text{C}_{27}\text{H}_{34}\text{N}_7\text{O}_5^+$: 536.2616; found: 536.2618.

5,7-Dinitro-4-(2,4,6-trimorpholinophenyl)benzo[c][1,2,5]oxadiazole (10). Dark blue solid, 75% yield, mp > 180 °C (dec.). ^1H NMR (CD_3CN , 599.7 MHz, 25 °C), δ (ppm): 8.95 (s, 1H), 6.73 (s, 2H), 3.92–3.79 (m, 4H), 3.40–3.33 (m, 4H), 3.29–3.18 (m, 8H), 2.77–2.57 (m, 8H). ^{13}C NMR (CD_3CN , 100.6 MHz, 25 °C), δ (ppm): 155.5, 154.1, 153.0, 147.2, 144.0, 135.8, 134.1, 128.5 (CH), 105.0, 104.9 (CH), 67.3 (CH_2), 67.1 (CH_2), 53.1 (CH_2), 49.0 (CH_2). MS (ES^+) m/z : 542 [$\text{M} + \text{H}$] $^+$, 564 [$\text{M} + \text{Na}$] $^+$; HRMS calc. for $\text{C}_{24}\text{H}_{28}\text{N}_7\text{O}_8^+$: 542.1994; found: 542.1997.

5,7-Dinitro-4-(2,4,6-tri(pyrrolidin-1-yl)phenyl)benzo[c][1,2,5]oxadiazole (11). ^1H NMR (CD_3CN , 300 MHz, 25 °C): δ , ppm: 8.93 (s, 1H), 6.41 (s, 2H), 4.00–3.00 (m, 12H), 2.10–1.80 (m, 12H).

General procedure for the synthesis of compounds 14–17

To a magnetically stirred solution of 12 or 13 (2×10^{-4} mol) dissolved in CD_3CN (5 mL and 10 mL, respectively), an equimolar amount of 7-chloro-4,6-dinitrobenzofuroxan (4) or 7-chloro-4,6-dinitrobenzofuroxan (5), was added at room temperature. ^1H -NMR analysis and TLC were used to monitor the reaction progress. Compound 14 was purified by precipitation from diethyl ether and light petroleum. Compound 15 was



purified by column chromatography on silica gel (FC), using as eluent diethyl ether/light petroleum (7 : 3). Compound **16** was isolated from the concentrated crude after treatment with a little amount of CH₂Cl₂ and removal of the unreacted phloroglucinol by filtration. Compound **17** was purified by column chromatography on silica gel (FC), using as eluent diethyl ether/light petroleum (2/8) then CH₂Cl₂/ethyl acetate 9/1. Although the reactions carried out in NMR spectroscopy tube showed conversion almost quantitative, the yields in isolated product were lower likely due to the purification methods, but we did not focus our efforts on yields optimization.

All the products were characterized by usual spectroscopic methods. Chemico-physical data are reported below.

2-(5,7-Dinitro-3-oxido-2,1,3-benzoxadiazol-4-yl)benzene-

1,3,5-triol (14). Red greasy solid, 54% yield. ¹H NMR (CD₃CN, 300 MHz, 25 °C), δ (ppm): 8.78 (s, 1H), 7.59 (br.s., 3H, OH), 6.02 (s, 1H). ¹³C NMR (CD₃CN, 100.56 MHz, 25 °C), δ (ppm): 162.7, 157.6, 146.0, 144.3, 135.8, 129.8, 129.1, 116.4, 95.9, 95.7. MS (ES⁺) *m/z*: 373 [M + Na]⁺, 389 [M + K]⁺. MS (ES⁻) *m/z*: 349 [M - H]⁻; HRMS calcd for C₁₂H₇N₄O₉⁺: 351.0208; found: 351.0205.

4,6-Dinitro-7-(2,4,6-trimethoxyphenyl)-2,1,3-benzoxadiazole 1-oxide (15). Red solid, 70% yield. ¹H NMR (CD₃CN, 300 MHz, 25 °C), δ (ppm): 8.80 (s, 1H), 6.34 (s, 2H), 3.92 (s, 3H), 3.73 (s, 6H, OCH₃). ¹³C NMR (CD₃CN, 150.80 MHz, 25 °C), δ (ppm): 166.1, 159.9, 146.0, 144.6, 135.9, 129.2, 129.0, 116.3, 97.9, 92.0, 56.8, 56.5. MS (ES⁺) *m/z*: 415 [M + Na]⁺; HRMS calcd for C₁₅H₁₃N₄O₉⁺: 393.0677; found: 393.0675.

2-(5,7-Dinitrobenzo[c][1,2,5]oxadiazol-4-yl)benzene-1,3,5-triol (16). Bordeaux red solid, 86% yield; ¹H NMR: (CD₃CN, 599.7 MHz, 25 °C), δ (ppm): 8.92 (s, 1H), 7.60 (br. s., 3H, OH), 6.10 (s, 2H). ¹³C NMR: (CD₃CN, 150.8 MHz, 25 °C), δ (ppm): 162.2, 157.1, 152.1, 148.0, 143.8, 136.3, 130.9, 128.2 (CH), 99.1, 96.0 (CH). MS (ES⁺) *m/z*: 357 [M + Na]⁺; HRMS calcd for C₁₂H₇N₄O₈⁺: 335.0258; found: 335.0260.

5,7-Dinitro-4-(2,4,6-trimethoxyphenyl)benzo[c][1,2,5]oxadiazole (17). Bordeaux red solid, 90% yield. ¹H NMR: (CD₃CN, 399.9 MHz, 25 °C), δ (ppm): 8.93 (s, 1H), 6.40 (s, 2H), 3.93 (s, 3H, OCH₃), 3.71 (s, 6H, OCH₃). ¹³C NMR: (CD₃CN, 100.6 MHz, 25 °C), δ (ppm): 165.7, 159.5, 152.1, 148.1, 143.8, 136.4, 130.4, 128.1 (CH), 101.3, 92.5 (CH), 56.7 (OCH₃), 56.4 (OCH₃). MS (ES⁺) *m/z*: 399 [M + Na]⁺; HRMS calcd for C₁₅H₁₃N₄O₈⁺: 377.0728; found: 377.0731.

Formation and detection of Wheland–Meisenheimer intermediates WM1–WM5

A solution of 1,3,5-triaminobenzene derivative (0.025 mmol) was dissolved in CDCl₃ or CD₂Cl₂ (1 mL) and introduced in a NMR spectroscopy tube that was inserted in the NMR probe. When the probe temperature reached -54 °C (in CDCl₃) or -80 °C (CD₂Cl₂), an equimolar amount of DNMB (5.17 mg, 0.025 mmol) was added to the solution, that became dark red-coloured, and the ¹H NMR spectrum was quickly recorded. The system was monitored at various times and at different temperatures until 25 °C. Immediately after the mixing, the spectrum showed the appearance of new signals, ascribed to zwitterionic intermediates WM, as confirmed by ¹³C NMR,

DEPT or g-HSQC experiments. On raising the temperature, signals belonging to WM gradually broadened and the return to the previous temperature lead to the re-appearance of sharp signals. Complexes WM1–WM5 resulted not stable for long time in solution, as noted when they were kept at room temperature for a night to record the ¹³C NMR spectra: the day after, the spectrum was complicated by the presence of new signals belonging to unidentified compounds. In the case of formation of WM4 and WM5 the integration of the signals revealed that the two species were formed in 42 : 58 percent relative molar ratio but we were not able to assign the signals of one or the other of these structures, thus, below, we describe the signals as belonging to the major (Maj) or the minor species (Min). The names of complexes WM1–WM5 have been created from ChemDraw Professional 17.1 version by drawing the canonical resonance form bearing the negative charge of the Meisenheimer moiety situated on the nitro group in *para* position with respect to the new bond formed and the positive charge of the Wheland moiety situated on the nitrogen atom of the amino substituent in *para* position to the new bond formed.

(6-Nitro-7-(4-(piperidin-1-ium-1-ylidene)-2,6-di(piperidin-1-yl)cyclohexa-2,5-dien-1-yl)benzo[c][1,2,5]oxadiazol-4(7H)-ylidene)azinate (WM1). ¹H NMR (400 MHz, CDCl₃, -54 °C), δ (ppm): 9.09 (s, 1H, H-5), 5.54 (s, 1H, H-10), 5.00 (br.s, 1H, H-12 or H-14), 4.93 (s, 1H, H-7), 4.82 (br.s, 1H, H-12 or H-14), 4.25–4.01 (m, 1H), 3.93–3.75 (m, 2H), 3.70–2.97 (ms, 9H), 1.95–1.32 (m, 18H). ¹³C NMR (CDCl₃, 100.6 MHz, -43 °C), δ (ppm): 161.0, 160.3, 159.4, 156.7, 146.5, 135.9 (CH), 120.2, 113.9, 91.0 (CH), 89.5 (CH), 49.9, 49.7, 49.5, 49.5 (2 sign. overl.), 49.3 (2 sign. overl.), 43.5 (CH, C-7), 40.2, (CH, C-10), 26.4, 26.3, 26.0, 24.4, 24.1, 24.0, 23.7 (2 signals overl.). ¹H NMR (400 MHz, CD₂Cl₂, -80 °C), δ (ppm): 8.91 (s, 1H, H-5), 5.52 (s, 1H, H-10), 4.90 (br.s, 2H, H-12 or H-14 and H-7), 4.75 (s, 1H, H-12 or H-14), 4.12–3.99 (m, 1H), 3.91–3.78 (m, 2H), 3.65–3.32 (ms, 3H), 3.23–2.85 (m, 6H), 1.99–1.30 (m, 6H). ¹³C NMR (CD₂Cl₂, 100.6 MHz, -80 °C): δ, ppm: 160.2, 159.8, 159.0, 146.3, 146.2, 135.4 (CH), 120.3, 113.2, 90.2 (CH), 89.1 (CH), 49.5 (CH₂), 49.3 (CH₂), 49.2 (CH₂), 49.1 (2 sign. overl., CH₂), 48.4 (CH₂), 43.2 (CH, C-7), 39.4, (CH, C-10), 26.9 (CH₂), 26.3 (CH₂), 25.9 (2 sign. overl., CH₂), 24.9 (CH₂), 24.0 (CH₂), 23.9 (2 sign. overl., CH₂), 23.4 (CH₂).

(7-(2,6-Dimorpholino-4-(morpholino-4-ium)cyclohexa-2,5-dien-1-yl)-6-nitrobenzo[c][1,2,5]oxadiazol-4(7H)-ylidene)azinate (WM2). ¹H NMR (600 MHz, CD₂Cl₂, -80 °C), δ (ppm): 8.97 (s, 1H, H-5), 5.58 (s, 1H), 4.98 (s, 1H), 4.94 (s, 1H), 4.74 (s, 1H), 4.50–4.34 (m, 1H), 4.10–2.81 (m.s, 23H). ¹³C NMR (CD₂Cl₂, 100.6 MHz, -80 °C): δ, ppm: 161.3, 160.8, 160.6, 146.2, 135.8, 135.5 (CH), 119.3, 113.3, 91.6 (CH), 90.3 (CH), 66.7 (br.s., CH₂), 65.5 (br.s., CH₂), 64.5 (br.s., CH₂, signals overlapped), 49.1 (br.s., CH₂, signals overlapped), 44.2 (CH), 39.2, (CH).

(6-Nitro-7-(4-(pyrrolidin-1-ium-1-ylidene)-2,6-di(pyrrolidin-1-yl)cyclohexa-2,5-dien-1-yl)benzo[c][1,2,5]oxadiazol-4(7H)-ylidene)azinate (WM3). ¹H NMR (400 MHz, CDCl₃, -54 °C), δ (ppm): 8.91 (s, 1H, H-5), 5.03 (d, 1H, *J* = 2.9 Hz, H-7), 4.82 (s, 1H, H-12 or H-14), 4.43 (s, 1H, H-12 or H-14), 4.38–4.30 (m, 1H, NCH), 4.20 (s, 1H, H-10), 3.79–3.67 (m, 1H, NCH), 3.51–3.38 (m, 3H, NCH), 3.38–3.29 (m, 1H, NCH), 3.29–3.19 (m, 1H, NCH), 3.19–3.03 (m, 2H, NCH₂), 3.03–2.90 (m, 2H, NCH₂), 2.90–2.80



(m, 1H, NCH), 2.20–2.05 (m, 4H, NCH₂CH₂), 2.05–1.87 (m, 8H, NCH₂CH₂). ¹³C NMR (CDCl₃, 100.6 MHz, –54 °C), δ (ppm): 158.2, 155.4, 155.2, 150.7, 134.1 (CH), 118.7, 113.8, 109.3, 104.8, 88.8 (CH), 87.6 (CH), 49.4 (CH₂), 49.2 (CH₂), 48.87 (CH₂), 48.86 (CH₂), 48.76 (CH₂), 48.4 (CH₂), 45.1 (CH, C-10), 41.0, (CH, C-7), 26.0 (CH₂), 25.7 (CH₂), 24.83 (CH₂), 24.79 (CH₂), 24.7 (CH₂), 24.6 (CH₂).

(7-(4-(Morpholino-4-ium)-2,6-di(piperidin-1-yl)cyclohexa-2,5-dien-1-yl)-6-nitrobenzo[c][1,2,5]oxadiazol-4(7H)-ylidene)azinate (WM4) and (7-(2-morpholino-4-(piperidin-1-ium-1-ylidene)-6-(piperidin-1-yl)cyclohexa-2,5-dien-1-yl)-6-nitrobenzo[c][1,2,5]oxadiazol-4(7H)-ylidene)azinate (WM5). Signals belonging to the major and minor compound present in the reaction mixture in 58/42 molar ratio are hereafter indicated as Maj and Min, respectively.

¹H NMR (400 MHz, CDCl₃, –54 °C), δ (ppm): 9.12 (s, 1H Min, H-5), 9.08 (s, 1H Maj, H-5), 5.61 (br.s., 1H Maj, H-12 or H-14), 5.56 (br.s., 1H Min, H-12 or H-14), 5.04 (s., 2H Maj + Min, H-7), 4.98 (br.s., 2H Maj + Min, H-12 or H-14), 4.84 (s, 1H Maj, H-10), 4.76 (s, 1H Min, H-10), 4.23–2.81 (m.s, 16H Maj + Min, OCH₂ and NCH₂), 2.00–1.31 (m.s, 12H Maj + Min, NCH₂CH₂, NCH₂CH₂CH₂). g-HSQC (CDCl₃, –54 °C): ¹H–¹³C correlations: 136.5–9.12, 136.3–9.08, 93.2–5.61, 91.3–5.56, 44.1–5.04, 91.9–4.98, 89.9–4.98, 40.5–4.84, 39.9–4.76, and 66.5–3.65, 66.4–3.62, 66.2–3.83, 65.3–3.62, 50.1–3.24, 50.0–3.09, 49.97–3.54, 49.87–3.85, 48.3–2.91, 26.8–1.77, 26.6–1.63, 24.3–1.60, 24.2–1.84, 26.5–1.45.

Study on the formation of σ-complexes M1–M6 by NMR spectroscopy

4,6-Dinitrobenzofuroxan (DNBF), 4,6-dinitrobenzofurazan (DNBZ), or 4,6-dinitrotetrazolopyridine (DNTP) (~4.4 × 10^{–5} mol) was dissolved in CD₃CN (0.3 mL) and the solution was cooled at –35 °C. This solution was added to an equimolar amount of compound **12** (or **13**) dissolved in CD₃CN (0.7 mL) and directly prepared in the NMR spectroscopy tube at –35 °C. The ¹H NMR spectra were recorded immediately after the mixing of the reagents and successively at intervals of 5–10 °C, from –35 °C to room temperature. At low temperature the spectrum showed non-equivalence of the hydrogen atoms belonging to the carbocyclic ring; on raising the temperature the signals broadened until to reach a coalescence situation. After, the peaks became sharp and a re-cooling produced again their broadening until to their splitting, as observed after the reagents mixing at low temperature. Complexes **M1** and **M3** were obtained in about 90% yield (calculated from ¹H NMR spectrum) while **M2** and **M4** are formed in CD₃CN in about 50% yield and, if kept in solution for three days or one night, respectively, evolved to the relevant substitution product **15** or **17**, as ascertained by comparison with authentic samples. ¹³C NMR spectrum of **M4** has not been reported because, recorded in acetonitrile during one night, it showed presence of signals belonging to the starting nucleophile and the substitution product **17**. The combination DNBZ/**12** was carried out in CD₃COCD₃ from –80 °C to +25 °C and also in this case the ¹H NMR spectrum recorded after having collected ¹³C NMR spectrum overnight showed presence of new signals belonging to

unidentified compounds; the ¹³C NMR signals reported below for **M3** have been selected and tentatively ascribed. Reactions of **12** and **13** with DNBF were also carried out at 25 °C in DMSO-d₆. Herein are reported NMR data obtained for complexes **M1–M6**; see ESI† section for further details.

(6-Nitro-1-oxido-7-(2,4,6-trihydroxyphenyl)benzo[c][1,2,5]oxadiazol-4(7H)-ylidene)azinate (M1). Red/orange solution, ¹H NMR (CD₃CN, 400 MHz, –35 °C), δ (ppm): 8.23 (d, *J* = 1.2 Hz, 1H), 7.04 (br.s, 3H), 5.90 (d, *J* = 1.9 Hz, 1H), 5.78 (d, *J* = 1.2 Hz, 1H), 5.76 (d, *J* = 1.9 Hz, 1H). ¹H NMR (DMSO-d₆, 400 MHz, 25 °C), δ (ppm): 8.57 (s, 1H), 5.68 (s, 1H), 5.65 (s, 2H). ¹³C NMR (CD₃CN, 100.56 MHz, –35 °C) δ (ppm): 158.7, 157.7, 157.2, 147.4, 141.9, 123.7, 114.1, 113.5, 97.1, 94.5, 94.2, 29.3.

(6-Nitro-1-oxido-7-(2,4,6-trimethoxyphenyl)benzo[c][1,2,5]oxadiazol-4(7H)-ylidene)azinate (M2). Red solution, ¹H NMR (CD₃CN, 400 MHz, –35 °C), δ (ppm): 8.27 (s, 1H), 6.25 (s, 1H), 6.07 (s, 1H), 5.84 (s, 1H), 3.91 (s, 3H), 3.76 (s, 3H), 3.53 (s, 3H). ¹H NMR (DMSO-d₆, 400 MHz, 25 °C) δ (ppm), δ (ppm): 8.61 (s, 1H), 6.17 (s, 2H), 5.79 (s, 1H), 3.73 (s, 6H), 3.70 (s, 3H). ¹³C NMR (DMSO-d₆, 150.80 MHz, 25 °C), δ (ppm): 161.2, 160.3, 149.7, 131.0, 127.3, 114.1, 110.3, 105.1, 91.4, 55.2, 55.1 (two signals overlapped), 28.8.

(6-Nitro-7-(2,4,6-trihydroxyphenyl)benzo[c][1,2,5]oxadiazol-4(7H)-ylidene)azinate (M3). Red solution, ¹H NMR (CD₃COCD₃, 400 MHz, –10 °C), δ (ppm): 8.40 (d, *J* = 1.4 Hz, 1H), 6.41 (d, *J* = 1.4 Hz, 1H), 6.10 (br.s., 1H), 5.86 (br.s., 1H), 4.47 (br.s., OH). ¹³C NMR (CD₃COCD₃, 150.8 MHz, 25 °C), δ (ppm): 158.1, 157.2, 152.7, 148.3, 144.1, 137.8, 128.6 (CH), 128.5, 96.4 (CH), 30.7 (CH).

(6-Nitro-7-(2,4,6-trimethoxyphenyl)benzo[c][1,2,5]oxadiazol-4(7H)-ylidene)azinate (M4). Red solution, ¹H NMR (CD₃CN, 400 MHz, –35 °C), δ (ppm): 8.31 (d, *J* = 1.4 Hz, 1H, H-7), 6.29 (d, *J* = 2.3 Hz, 1H, H-12 or 14), 6.17 (d, *J* = 1.4 Hz, 1H, H-10), 6.06 (d, *J* = 2.3 Hz, 1H, H-12 or 14), 3.94 (s, 3H, CH₃), 3.77 (s, 3H, CH₃), 3.46 (s, 3H, CH₃).

(6-Nitro-5-(2,4,6-trihydroxyphenyl)tetrazolo[1,5-*a*]pyridin-8(5H)-ylidene)azinate (M5). Red solution, ¹H NMR (CD₃CN, 600 MHz, –35 °C), δ (ppm): 8.49 (s, 1H), 7.48 (s, 1H), 5.93 (s, 1H), 5.78 (s, 1H). ¹³C NMR (CD₃CN, 150.80 MHz, –35 °C), δ (ppm): 159.7, 157.3, 153.6, 142.8, 128.0, 127.4, 104.5, 102.3, 94.6, 93.9, 53.7, 30.4.

(6-Nitro-5-(2,4,6-trimethoxyphenyl)tetrazolo[1,5-*a*]pyridin-8(5H)-ylidene)azinate (M6). Red solution, ¹H NMR (CD₃CN, 400 MHz, –35 °C), δ (ppm): 8.52 (s, 1H), 7.61 (s, 1H), 6.27 (br.s, 1H), 6.09 (br.s, 1H), 3.95 (br.s, 3H), 3.78 (s, 3H), 3.51 (br.s, 3H). ¹³C NMR (CD₃CN, 150.80 MHz, –35 °C), δ (ppm): 159.7, 157.3, 153.6, 142.8, 128.0, 127.4, 104.5, 102.3, 94.6, 93.9, 53.7.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors are grateful, for the financial support, to Alma Mater Studiorum – Università di Bologna (RFO funds). Many thanks to Prof. Daniele Casarini for line shape simulation, Dr



Leonardo Iannuzzo, Dr Francesco Giarratano and Mr Luca Zuppiroli for mass spectra.

Notes and references

- G. N. Nikonov and S. Bobrov, 1,2,5-Oxadiazoles, in *Comprehensive Heterocyclic Chemistry III*, ed. A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven and R. J. K. Taylor, Elsevier, 2008, Vol. 5, p. 315.
- (a) A. Gasco and A. J. Boulton, *Adv. Heterocycl. Chem.*, 1981, **29**, 251; (b) P. B. Ghosh, B. Terna and M. W. Whitehouse, *Med. Res. Rev.*, 1981, **2**, 158.
- (a) H. Cerecetto and W. Porcal, *Mini-Rev. Med. Chem.*, 2005, **5**, 57; (b) E. Chugunova, C. Boga, I. Sazykin, S. Cino, G. Micheletti, A. Mazzanti, M. Sazykina, A. Burilov, L. Khmelevtsova and N. Kostina, *Eur. J. Med. Chem.*, 2015, **93**, 349.
- C. Medana, A. Di Stilo, S. Visentin, R. Fruttero, A. Gasco, D. Ghigo and A. Bosia, *Pharm. Res.*, 1999, **16**, 956.
- (a) J. F. Callan, A. P. de Silva, J. Ferguson, A. J. M. Huxley and A. M. O'Brien, *Tetrahedron*, 2004, **60**, 11125; (b) F. Davi and D. Rinaldi, *J. Elastoplast.*, 2015, **120**, 197.
- C. K. Lowe-Ma, R. A. Nissan and W. S. Wilson, *J. Org. Chem.*, 1990, **55**, 3760.
- (a) F. Terrier, *Nucleophilic Aromatic Displacement*, ed. H. Feuer, VCH, New York, 1991; (b) F. Terrier, *Modern Nucleophilic Aromatic Substitution*, John Wiley & Sons, New York, 2013.
- F. Terrier, S. Lakhdar, T. Boubaker and R. Goumont, *J. Org. Chem.*, 2005, **70**, 6242.
- S. Lakhdar, R. Goumont, F. Terrier, T. Boubaker, J. M. Dust and E. Buncel, *Org. Biomol. Chem.*, 2007, **5**, 1744.
- F. Terrier, *Chem. Rev.*, 1982, **82**, 77.
- E. Buncel, J. M. Dust and F. Terrier, *Chem. Rev.*, 1995, **95**, 2261.
- C. Boga and L. Forlani, *J. Chem. Soc., Perkin Trans. 2*, 2001, 1408.
- C. Boga, E. Del Vecchio, L. Forlani, A. Mazzanti and P. E. Todesco, *Angew. Chem., Int. Ed.*, 2005, **44**, 3285.
- C. Boga, E. Del Vecchio, L. Forlani, A. Mazzanti, C. Menchen Lario, P. E. Todesco and S. Tozzi, *J. Org. Chem.*, 2009, **74**, 5568.
- (a) H. Mayr and M. Patz, *Angew. Chem., Int. Ed. Engl.*, 1994, **33**, 938; (b) H. Mayr, B. Kempf and A. R. Ofial, *Acc. Chem. Res.*, 2003, **36**, 66; (c) H. Mayr, M. Patz, M. F. Gotta and A. R. Ofial, *Pure Appl. Chem.*, 1998, **70**, 1993; (d) H. Mayr, T. Bug, M. F. Gotta, N. Hering, B. Irrgang, B. Janker, B. Kempf, R. Loos, A. R. Ofial, G. Remmenikov and N. Schimmel, *J. Am. Chem. Soc.*, 2001, **123**, 9500; (e) H. Mayr and A. R. Ofial, *Acc. Chem. Res.*, 2016, **49**, 952 and ref. therein; (f) H. Mayr, *Tetrahedron*, 2015, **71**, 5095.
- (a) F. Terrier, S. Lakhdar, R. Goumont, T. Boubaker and E. Buncel, *Chem. Commun.*, 2004, 2586; (b) S. Lakhdar, R. Goumont, F. Terrier, T. Boubaker, J. M. Dust and E. Buncel, *Org. Biomol. Chem.*, 2007, **5**, 1744.
- C. Boga, E. Del Vecchio, L. Forlani, R. Goumont, F. Terrier and S. Tozzi, *Chem.-Eur. J.*, 2007, **13**, 9600.
- L. Forlani, C. Boga, A. Mazzanti and N. Zanna, *Eur. J. Org. Chem.*, 2012, **6**, 1123.
- A. Hagfeldt, G. Boschloo, L. Sun, L. Kloo and H. Pettersson, *Chem. Rev.*, 2010, **110**, 6595.
- G. S. He, L.-S. Tan, Q. Zheng and P. N. Prasad, *Chem. Rev.*, 2008, **108**, 1245.
- A. K. S. Mehilal, R. B. Salunk and N. Sikder, *New J. Chem.*, 2001, **25**, 1549.
- A. K. S. Mehilal, R. B. Salunke and N. Sikder, *J. Energ. Mater.*, 2002, **20**, 39.
- G. Micheletti, S. Bordoni, E. Chugunova and C. Boga, *Molecules*, 2017, **22**, 684.
- F. Effenberger and R. Niess, *Angew. Chem., Int. Ed. Engl.*, 1967, **6**, 1067.
- F. Effenberger, *Acc. Chem. Res.*, 1989, **22**, 27.
- F. Effenberger and R. Niess, *Chem. Ber.*, 1968, **101**, 3787.
- T. Yamaoka, H. Hosoya and S. Nagakura, *Tetrahedron*, 1968, **24**, 6203.
- T. Yamaoka, H. Hosoya and S. Nagakura, *Tetrahedron*, 1970, **26**, 4125.
- W. Knoche, W. Sachs and S. Vogel, *Bull. Soc. Chim. Fr.*, 1988, 377.
- W. Knoche, W. W. Schoeller, R. Schomaecker and S. Vogel, *J. Am. Chem. Soc.*, 1988, **110**, 7484.
- W. Sachs, W. Knoche and S. Herrmann, *J. Chem. Soc., Perkin Trans. 2*, 1991, **2**, 701.
- D. T. Glatzhofer, D. Allen and R. W. Taylor, *J. Org. Chem.*, 1990, **55**, 6229.
- P. Menzel and F. Effenberger, *Angew. Chem., Int. Ed. Engl.*, 1972, **11**, 922.
- F. Effenberger, P. Menzel and W. Seufert, *Chem. Ber.*, 1979, **112**, 1660.
- R. Niess, K. Nagel and F. Effenberger, *Tetrahedron Lett.*, 1968, 4265.
- F. Effenberger, K. E. Mack, K. Nagel and R. Niess, *Chem. Ber.*, 1977, **110**, 165.
- P. Fkher, K. E. Mack, E. Mhsner and F. Effenberger, *Chem. Ber.*, 1977, **110**, 181.
- P. Menzel and F. Effenberger, *Angew. Chem., Int. Ed. Engl.*, 1975, **14**, 62.
- F. Effenberger, W. Agster, P. Fischer, K. H. Jogun, J. J. Stezowski, E. Daltrozzo and G. Kollmannsberger-von Nell, *J. Org. Chem.*, 1983, **48**, 4649.
- C. Boga, L. Forlani, S. Tozzi, E. Del Vecchio, A. Mazzanti, M. Monari and N. Zanna, *Curr. Org. Chem.*, 2014, **18**, 512.
- C. Boga, E. Del Vecchio and L. Forlani, *Eur. J. Org. Chem.*, 2004, 1567.
- C. Boga, E. Del Vecchio, L. Forlani and S. Tozzi, *J. Org. Chem.*, 2007, **72**, 8741.
- L. Forlani, C. Boga, E. Del Vecchio, A. L. T. D. Ngobo and S. Tozzi, *J. Phys. Org. Chem.*, 2007, **20**, 201.
- C. Boga, E. Del Vecchio, S. Tozzi, L. Forlani, M. Monari, G. Micheletti and N. Zanna, *ARKIVOC*, 2014, (iv), 51.
- E. Del Vecchio, C. Boga, L. Forlani, S. Tozzi, G. Micheletti and S. Cino, *J. Org. Chem.*, 2015, **80**, 2216.
- C. Boga, G. Micheletti, S. Cino, S. Fazzini, L. Forlani, N. Zanna and D. Spinelli, *Org. Biomol. Chem.*, 2016, **14**, 4267.



- 47 G. Micheletti, C. Boga, M. Pafundi, S. Pollicino and N. Zanna, *Org. Biomol. Chem.*, 2016, **14**, 768.
- 48 S. Lakhdar, M. Westermaier, F. Terrier, R. Goumont, T. Boubaker, A. R. Ofial and H. Mayr, *J. Org. Chem.*, 2006, **71**, 9088.
- 49 Y. P. Semenyuk, P. G. Morozov, O. N. Burov, M. E. Kletskii, A. V. Lisovin, S. V. Kurbatov and F. Terrier, *Tetrahedron*, 2016, **72**, 2254.
- 50 O. Exner, *Advances in Linear Free Energy Relationship*, ed. N. B. Chapman and J. Shorter, Plenum Press, London, 1972.
- 51 G. Micheletti, C. Boga, L. Forlani, E. Del Vecchio, N. Zanna, A. Mazzanti and M. Monari, *Eur. J. Org. Chem.*, 2017, 964.
- 52 W. B. Jennings, *Chem. Rev.*, 1975, **75**, 307.
- 53 K. Mislow and M. Raban, *Top. Stereochem.*, 1967, **1**, 1.
- 54 (a) J.-C. Hallé, M.-P. Simonnin, M.-J. Pouet and F. Terrier, *Tetrahedron Lett.*, 1983, **24**, 2255; (b) J.-C. Hallé, M.-J. Pouet, M.-P. Simonnin, F. Debleds and F. Terrier, *Can. J. Chem.*, 1982, **60**, 1988; (c) M.-P. Simonnin, J.-C. Hallé, F. Terrier and M.-J. Pouet, *Can. J. Chem.*, 1985, **63**, 866.
- 55 (a) F. Terrier, M.-J. Pouet, J.-C. Halle, E. Kizilian and E. Buncel, *J. Phys. Org. Chem.*, 1998, **11**, 707; (b) J. C. Halle, M. J. Pouet, M. P. Simonnin and F. Terrier, *Tetrahedron Lett.*, 1985, **26**, 1307.
- 56 J. Sandstrom, *Dynamic NMR Spectroscopy*, Academic Press, London, 1982, p. 99.
- 57 *Dynamic Nuclear Magnetic Resonance Spectroscopy*, ed. L. M. Jackman and F. A. Cotton, Academic Press, New York, 1975.
- 58 *QCPE program no. 633*, Indiana University, Bloomington, IN, USA.
- 59 A. Tatarov, S. Kurbatov, G. Borodkin, R. Goumont and F. Terrier, *Tetrahedron*, 2010, **66**, 995.

